Skip Menuenglish.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Drug-induced colour vision disorders

FEATURED REVIEW Acquired colour vision disorders may be caused by ocular, neurological or metabolic disorders, but they can also be drug-induced. In some cases, these disorders may precede or reveal the onset of severe and sometimes irreversible eye damage. The drugs implicated mainly include: phosphodiesterase type 5 inhibitors such as sildenafil; digoxin; anti-infectives including interferon alfa; ethambutol; metronidazole; and some antimalarials.
Full review (3 pages) available for download by subscribers.
1 May 2012

In the May issue of Prescrire International: 2011 drug packaging review.
Too many dangers and too many patients overlooked

FREE DOWNLOAD Every year, Prescrire's analysis of drug packaging confirms the importance of taking packaging into account in assessing a drug's harm-benefit balance.
Full text available for free download.
1 May 2012

Warts: spontaneous healing is frequent

Plantar warts have a high healing rate over time. Treatments make little difference.
1 May 2012

Tianeptine (Stablon°) as an antidepressant: too high a risk of dependence

Tianeptine (Stablon°), marketed as an antidepressant, should be avoided as it carries a high risk of dependence. The risks have been known for a number of years, but health authorities are still ignoring them.
1 May 2012

Adverse effects: means of increasing reporting

Effective local initiatives have been set up in several French regions to improve the gathering of reports of adverse effects.
1 May 2012

Prescrire: financial transparency, editorial independence

Prescrire makes its accounts public every year.
1 May 2012

No grants. No advertising. No conflicts of interest.

Every year Association Mieux Prescrire (AMP), the French non-profit that publishes Prescrire and Prescrire International, publishes its accounts in full. This allows readers to see exactly where our money goes – and especially where it comes from.
1 May 2012

A new drug treatment makes headlines in France:
olanzapine + topiramate (Obéfix°), maintains ideal weight without risk

BREAKING NEWS Dateline Paris, 1 April 2012. French medical journal La revue Prescrire has revealed unbelievable new results that will be welcome reading for medical professionals and patients alike. A new combination drug, soon to be launched under the brand name Obéfix°, promises to change the way we think about maintaining an ideal weight.
1 April 2012

• Decline in vigilance: a danger to public health!

We all need an annual April "booster shot", to help us to take a good look at our perception of information.
1 April 2012

Boceprevir (Victrelis°). In triple-drug combination: virological advantage in chronic hepatitis C

FEATURED REVIEW  In chronic hepatitis C caused by genotype 1 virus, adding boceprevir to the standard combination of peginterferon alfa + ribavirin markedly increases the rate of sustained virological response, with acceptable adverse effects. Thus, the addition of boceprevir to standard therapy is justified, but evaluation must continue to determine long-term clinical outcomes.
Full review (4 pages) available for download by subscribers.
1 April 2012

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90